No Data
No Data
No Data
No Data
No Data
Yestar Healthcare Faces Second Arbitration Related to Trading Firm Acquisition
Yestar Healthcare Holdings (HKG:2393) received a notice of a second arbitration related to its acquisition of a 70% stake in Guangzhou Shengshiyuan Trading, according to a filing with the Hong Kong Ex
MT NewswiresApr 9 02:17 ET
Superstar Healthcare Holdings (02393): Leung Chun-hung resigns as executive director
Superstar Medical Holdings (02393) announced that Leung Chun-hung undertakes other duties related to his future career and business development...
Zhitong FinanceMar 28 04:58 ET
Superstar Medical Holdings (02393) announced annual results. Losses attributable to shareholders of 13.888 million yuan narrowed 98.6% year-on-year
According to the Zhitong Finance App, Superstar Medical Holdings (02393) announced its annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 2,913 billion yuan (RMB, same below) during the period, an increase of 3.86% over the previous year; losses attributable to shareholders were 13.888 million yuan, a year-on-year decrease of 98.6%; and a basic loss of 0.6 points per share. According to the announcement, demand for the Group's in vitro diagnostic consumables increased in 2023, mainly due to a sharp rise in demand for cardiomyocardial products from patients with diseases caused by COVID-19 in the first quarter of 2023. Receipts from continuing operations in this segment
Zhitong FinanceMar 27 09:42 ET
YESTAR HEALTH: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Futu NewsMar 27 09:28 ET · Announcements
Superstar Medical Holdings (02393.HK) expects net loss of not more than 10 million yuan in fiscal year 2023
Gelonghui, March 15, 丨 Superstar Medical Holdings (02393.HK) announced that compared to the Group's audited net loss of approximately RMB 1.02 billion for the year ended December 31, 2022, the Group expects a sharp reduction in fiscal year 2023 and recorded a net loss of not more than RMB 10 million. The Group expects a sharp decrease in net losses in fiscal year 2023 mainly due to (i) a sharp reduction in impairment losses on goodwill and other intangible assets in fiscal year 2023; (ii) impairment losses on the return of some financial assets; and (iii) a sharp drop in financial costs.
Gelonghui FinanceMar 15 07:30 ET
YESTAR HEALTH: PROFIT WARNING
Futu NewsMar 15 07:26 ET · Announcements
No Data
No Data